Semaglutide is a GLP-1 receptor agonist studied for type 2 diabetes and for chronic weight management. The STEP weight-loss program and the SELECT cardiovascular trial are the backbone of what we actually know — not clinic ads or social media before-and-afters.
Key facts
- STEP 1: in adults with overweight or obesity without diabetes, once-weekly semaglutide produced substantially greater weight loss than placebo at 68 weeks.1
- STEP 2: benefit extends to adults with type 2 diabetes, who typically lose less weight than people without diabetes.2
- STEP 4: after weight loss on semaglutide, switching to placebo led to substantial regain versus continuing the drug.4
- STEP 5: two-year data support maintained weight reduction with continued treatment versus placebo.5
- SELECT: fewer major cardiovascular events in people with overweight/obesity and established CVD without diabetes.6
- SUSTAIN-6: cardiovascular benefit in type 2 diabetes at high cardiovascular risk.7
What the STEP program tested
STEP is a series of randomized trials of once-weekly semaglutide for weight management. STEP 1 enrolled adults with a body-mass index in the overweight or obesity range without diabetes; both arms received lifestyle intervention. Mean weight change favored semaglutide over placebo by a wide margin, with gastrointestinal adverse events more common on drug.1
STEP 2 asked the same class of question in type 2 diabetes. Average weight loss was smaller than in STEP 1 — expected in diabetes populations — but still greater than placebo.2 STEP 3 layered intensive behavioral therapy; semaglutide still added weight-loss benefit beyond the behavioral program alone.3
STEP 4 is the maintenance and withdrawal trial: after losing weight on semaglutide, participants continued drug or switched to placebo. Continuation preserved more of the loss; placebo led to substantial regain.4 STEP 5 followed people for two years and found sustained weight reduction with ongoing treatment compared with placebo.5
Cardiovascular outcomes
SUSTAIN-6 evaluated cardiovascular safety and outcomes in type 2 diabetes at high cardiovascular risk and found a reduction in major adverse cardiovascular events with semaglutide versus placebo.7 SELECT enrolled people with overweight or obesity and pre-existing cardiovascular disease without diabetes and likewise found fewer major cardiovascular events on semaglutide.6
Neither trial means “semaglutide is heart medicine for everyone.” They mean that in the enrolled high-risk groups, under trial conditions, hard cardiovascular endpoints improved. Extrapolating to low-risk people using the drug only for appearance is marketing, not SELECT.
Benefits and harms, side by side
| Domain | Evidence snapshot |
|---|---|
| Weight loss vs placebo | Strong across STEP 1–3 and 5 in eligible adults15 |
| Weight after stopping | Substantial regain after withdrawal (STEP 4)4 |
| CV events (defined high-risk groups) | Reduced in SUSTAIN-6 (T2D) and SELECT (obesity + CVD, no diabetes)67 |
| GI tolerability | Nausea, vomiting, diarrhea, constipation common; lead to discontinuation for some1 |
| Universal cosmetic use without indication | Not what the pivotal programs were designed to prove |
What this page will not do
It will not tell you how to dose, source, or stack semaglutide. It will not treat compounded or “research” products as equivalent to the pharmaceutical product used in STEP and SELECT. It will not promise that your results will match a trial mean.
Frequently asked questions
Is Wegovy the same as Ozempic?
Both contain semaglutide; labeled indications and product presentations differ. Efficacy claims should point to the trial that matches the use case (diabetes care vs chronic weight management), not to a brand nickname.
Will I regain weight if I stop?
STEP 4 found substantial regain after switching from semaglutide to placebo compared with continued treatment. Individual courses vary, but regain risk is part of the evidence base, not a rare footnote.
Does semaglutide prevent heart attacks in everyone who takes it?
No. SELECT and SUSTAIN-6 support cardiovascular benefit in specific high-risk populations. That is clinically important and still narrower than popular claims.
Are lifestyle changes irrelevant if I’m on the drug?
The pivotal weight trials included lifestyle intervention in both arms. The drug’s advantage is measured on top of that context, not instead of medical and behavioral care.
The bottom line
Semaglutide has high-quality evidence for weight reduction in eligible adults and for fewer major cardiovascular events in defined high-risk groups. It also has clear evidence that stopping often undoes much of the weight benefit. Treat it as a studied prescription therapy with tradeoffs — not as a short-cut cosmetic injection with trial-grade proof for every Instagram use case.